3Chwab ME, Kapthammer JP, Bandtlow CE. Inhibitors of neurite growth . Annu Rev Neurosci, 1993,16:565- 595.
4Nash HH, Borke RC, Anders JJ. Ensheathing cells and methylprednisolone promote axonal regeneration and functional recovery in the lesioned adult rat spinal cord. Neurosci , 2002, 22:7111- 7120 .
5Topsakal C, Erol FS, Ozveren MF, et al. Effects of methylprednisolone and dextromethorphan on lipid peroxidation in an experimental model of spinal cord injury. Neurosurg Rev, 2002,25:258- 266.
6Hall ED. Pharmacological treatment of acute spinal cord injury: how do we build on past success? J Spinal Cord Med,2001,24 :142- 146.
7Merola A, O'Brien MF, Castro BA, et al. Histologic characterization of acute spinal cord injury treated with intravenous methylprednisolone. J Orthop Trauma, 2002, 16:155- 161.
8Hayashi M, Ueyama T, Tamaki T, et al. Expression of neurotrophin and IL-1 beta mRNAs following spinal cord injury and the effects of methylprednisolone treatment. Kaibogaku Zasshi, 1997, 72:209- 213.
9Dougherty KD, Dreyfus CF, Black IB. Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury. Neurobiol Dis, 2000, 7:574-585.
10Nash HH, Borke RC, Anders JJ. Ensheathing cells and methylprednisolone promote axonal regeneration and functional recovery in the lesioned adult rat spinal cord. Neurosci, 2002, 22:7111- 7120.
6Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey[ J~. Spinal Cord,2006,44(9) :523 -529.
7Stoica B, Byrnes K, Faden AI. Multifunctional drug treatment in neurotrauma[ J]. Neurotherapeutics,2009,6( 1 ) :14 -27.
